Article Text

Download PDFPDF
Survival of Patients With Mucinous Ovarian Carcinoma and Ovarian Metastases: A Population-Based Cancer Registry Study
  1. Michiel Simons, MD*,
  2. Nicole Ezendam, PhD,,
  3. Johan Bulten, MD, PhD*,
  4. Iris Nagtegaal, MD, PhD* and
  5. Leon Massuger, MD, PhD§
  1. *Department of Pathology, Radboud University Medical Center, Nijmegen;
  2. Eindhoven Cancer Registry, Eindhoven;
  3. Department of Medical Psychology, Tilburg University, Tilburg; and
  4. §Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.
  1. Address correspondence and reprint requests to Michiel Simons, MD, Department of Pathology, Radboud University Medical Center, 824, PO Box 9101, 6500 HB Nijmegen, the Netherlands. E-mail: Michiel.Simons{at}


Objectives Patients with mucinous ovarian carcinoma (MOC) generally have a favorable prognosis, although in advanced stage, prognosis is significantly worse compared to patients with serous ovarian carcinomas (SOCs). This might be due to the difficulties in distinguishing MOC from metastatic tumors. In the current study, we investigate prognosis of MOC compared to other types of ovarian cancer and to synchronous metastases to the ovary (sMO).

Materials and Methods Age, laterality, International Federation of Gynecology and Obstetrics stage, tumor grade, treatment, and survival were extracted from the Eindhoven Cancer registry for all patients diagnosed with ovarian carcinomas or sMO between 1990 and 2012. Five-year survival analysis and Cox proportional hazards analysis were conducted.

Results A total of 3556 patients with primary ovarian carcinoma (of which 474 mucinous) and 289 with sMO were identified. In advanced stage, 5-year survival of patients with MOC was comparable to survival of patients with sMO (11% vs 11%, P = 0.32) and decreased compared to patients with SOC (26%, P < 0.01). For MOC, there was no clinically significant effect on 5-year survival of either debulking (12% vs 8%, P < 0.01) or chemotherapy (12% vs 10%, P = 0.02).

Conclusions Patients with advanced stage MOC have a worse prognosis than advanced stage SOC. Survival is almost identical to that of patients with sMO. Effects of chemotherapy and debulking are limited in patients with MOC, which may be explained by suboptimal treatment due to the admixture of metastases in advanced stage MOC. Methods to differentiate between primary MOC and metastatic disease are needed to provide optimal treatment and insight in prognosis.

  • Ovarian cancer
  • Mucinous ovarian carcinoma
  • Metastasis
  • Survival

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.